TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29872876

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha 2-a (PEG-IFN α-2a) therapy
Number of subjects: 292

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 292
Study: 26798658

Group type: EXPERIMENTAL
Intervention: CSII + Sig group
Number of subjects: 60

Group type: COMPARATOR
Intervention: CSII group
Number of subjects: 60
Study: 25822572

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1 mL of methylprednisolone acetate, 40 mg/mL, dissolved in 4 mL of lidocaine hydrochloride, 10 mg/mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo injection (1 mL isotonic saline mixed with 4 mL of lidocaine hydrochloride, 10 mg/mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Corticosteroid vs Placebo
Number of subjects: 100
Study: 24430056

Group type: EXPERIMENTAL
Intervention: Lantoks injections in spastic muscles
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard treatment (massage, exercise therapy, FTL, pharmacotherapy)
Number of subjects: 27
Study: 20003966

Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy (GJJ)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 39
Study: 18779281

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 16377361

Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 395
Study: 12886239

Group type: EXPERIMENTAL
Intervention: IFN/HU
Number of subjects: 534

Group type: COMPARATOR
Intervention: HU
Number of subjects: 534
Study: 10984564

Group type: EXPERIMENTAL
Intervention: Inactivated-poliovirus vaccine (IPV), administered subcutaneously
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Trivalent OPV (manufactured in the United States or in Europe)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Monovalent type 3 OPV
Number of subjects: 1025
Study: 9076288

Group type: EXPERIMENTAL
Intervention: Letter of invitation for a flu vaccine
Number of subjects: 2791

Group type: EXPERIMENTAL
Intervention: Offer of a free flu vaccine
Number of subjects: 2791

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2791
Study: 8436631

Group type: EXPERIMENTAL
Intervention: Periodontally treated patients with > 5 new DFS% during the 3rd 4-year period (years 9-12)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients with new root caries lesions
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients with root caries incidence between 1 and 5 new DFS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients with root caries incidence between 6 and 9 new DFS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients with root caries incidence of 12 or more new DFS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Annual mean number of new DFS
Number of subjects: 27
Study: 3784919

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Liposom
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Veralipride
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31064743

Group type: EXPERIMENTAL
Intervention: Cancer decision-support tools available and used
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Cancer decision-support tools available and likely to be used
Number of subjects: 476

Group type: COMPARATOR
Intervention: Practices with cancer decision-support tools
Number of subjects: 476
Study: 27816913

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (4 joules/cm², total dose = 40 joules)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 73
Study: 25593121

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted catheter-directed thrombolysis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional catheter-directed thrombolysis
Number of subjects: 48
Study: 23962386

Group type: EXPERIMENTAL
Intervention: Tightness of cuff during knee-extension exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin and subcutaneous fat thickness
Number of subjects: 0
Study: 21106340

Group type: EXPERIMENTAL
Intervention: Closed endotracheal suctioning (CES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Open endotracheal suctioning (OES)
Number of subjects: 200
Study: 20066964

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg with sucrose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg with sucrose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acarbose with starch
Number of subjects: 100
Study: 17185007

Group type: EXPERIMENTAL
Intervention: High impact anaerobic sprints
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low impact aerobic running
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 27
Study: 15083524

Group type: EXPERIMENTAL
Intervention: Lorazepam (single-dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study: 11435512

Group type: EXPERIMENTAL
Intervention: Milk-based cereal and nutritional counseling
Number of subjects: 418

Group type: COMPARATOR
Intervention: Nutritional counseling alone
Number of subjects: 418

Group type: COMPARATOR
Intervention: Visitation group (control for morbidity ascertainment)
Number of subjects: 418

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 418
Study: 9492730

Group type: EXPERIMENTAL
Intervention: Non-closure of both visceral and parietal peritoneum (study group, n = 179)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Closure of both layers (control group, n = 182)
Number of subjects: 361
Study: 11271231

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 540

Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: FK 506 (after conversion from cyclosporin A)
Number of subjects: 540
Study: 3051072

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 7964959

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN) started at 1 x 10(6) U/m2 SC three times per week, escalating to a maximum of 3 x 10(6) U/m2 SC three times per week for 6 months.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study: 282082

Group type: EXPERIMENTAL
Intervention: Nurse practitioner care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician care
Number of subjects: 0
Study: 31950527

Group type: EXPERIMENTAL
Intervention: Peer counseling support during the first 3 months after childbirth from 10 peers with successful breastfeeding experiences.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine education provided by health centers (Control).
Number of subjects: 80
Study: 30689258

Group type: EXPERIMENTAL
Intervention: PEG‐IFN add‐on therapy
Number of subjects: 234

Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PEG‐IFN add‐on therapy in PEG‐IFN naive patients with HBsAg <4000 IU/mL and HBV DNA <50 IU/mL
Number of subjects: 234

Group type: COMPARATOR
Intervention: ETV monotherapy in PEG‐IFN naive patients with HBsAg <4000 IU/mL and HBV DNA <50 IU/mL
Number of subjects: 234
Study: 28198661

Group type: EXPERIMENTAL
Intervention: Occupation-based approach using Aid for Decision-Making in Occupation Choice (ADOC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Impairment-based approach
Number of subjects: 48
Study: 25670362

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg/day
Number of subjects: 0
Study: 22820629

Group type: EXPERIMENTAL
Intervention: GameBike
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional stationary bikes
Number of subjects: 36
Study: 21835287

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon counterpulsation (IABC)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 499
Study: 20042788

Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA for 20 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (2 mA for 1 min)
Number of subjects: 20
Study: 16753373

Group type: EXPERIMENTAL
Intervention: 150 mg bicalutamide daily
Number of subjects: 3292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3292

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 3292
Study: 15005441

Group type: EXPERIMENTAL
Intervention: Fluoride mouthrinse with essential oils
Number of subjects: 153

Group type: COMPARATOR
Intervention: Fluoride nonessential oils mouthrinse (positive control)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Essential oil nonfluoride mouthrinse (negative control)
Number of subjects: 153
Study: 12199263

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 100
Study: 9829605

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) supplementation (0.15 mg/kg/d) during total parenteral nutrition (TPN)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 28

Group type: COMPARATOR
Intervention: None (control group receiving no rhGH)
Number of subjects: 28
Study: 8067698

Group type: EXPERIMENTAL
Intervention: DDP (cisplatin)
Number of subjects: 22
Study: 2688065

Group type: EXPERIMENTAL
Intervention: Sucralfate (4 g)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prednisolone metasulphobenzoate (20 mg)
Number of subjects: 44
Study: 5310209

Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg twice daily for 20 days)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 215
Study: 31415194

Group type: EXPERIMENTAL
Intervention: Me & You intervention
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 709
Study: 28911287

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 160

Group type: COMPARATOR
Intervention: Neostigmine/Atropine
Number of subjects: 160
Study: 25057991

Group type: EXPERIMENTAL
Intervention: Intraoperative cervical dilatation
Number of subjects: 208

Group type: COMPARATOR
Intervention: No intraoperative cervical dilatation (Control)
Number of subjects: 208
Study: 23389298

Group type: EXPERIMENTAL
Intervention: Oral glutamine (Gln)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21778352

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 900 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18623910

Group type: EXPERIMENTAL
Intervention: Recombinant parathyroid hormone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study: 16495253

Group type: EXPERIMENTAL
Intervention: FPV 1,400 mg BID plus RTV 100 mg BID
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FPV 1,400 mg BID plus RTV 200 mg BID
Number of subjects: 42

Group type: COMPARATOR
Intervention: FPV 700 mg BID plus RTV 100 mg BID
Number of subjects: 42
Study: 12451441

Group type: EXPERIMENTAL
Intervention: Levodopa (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11482295

Group type: EXPERIMENTAL
Intervention: Computerized treatment simulation presentation
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard presurgical consultation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Treatment simulation group
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard presurgical consultation group
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Overall expectations related to psychological distress and gender
Number of subjects: 146
Study: 9569113

Group type: EXPERIMENTAL
Intervention: Ejaculation (study group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No ejaculation (control group)
Number of subjects: 25
Study: 8308570

Group type: EXPERIMENTAL
Intervention: Isolated soybean protein + soybean cotyledon fiber
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Isolated soybean protein + cellulose
Number of subjects: 21

Group type: COMPARATOR
Intervention: Casein + soybean cotyledon fiber
Number of subjects: 21

Group type: COMPARATOR
Intervention: Casein + cellulose
Number of subjects: 21
Study: 2737719

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 3234
Study: 4755182

Group type: EXPERIMENTAL
Intervention: Prostaglandin E(1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low concentrations of prostaglandins
Number of subjects: 0
Study: 31084288

Group type: EXPERIMENTAL
Intervention: Therapeutic horse riding (20-week intervention)
Number of subjects: 12
Study: 31030981

Group type: EXPERIMENTAL
Intervention: Protocol-guided individualised nutritional support to reach protein and caloric goals
Number of subjects: 2088

Group type: COMPARATOR
Intervention: Standard hospital food
Number of subjects: 2088
Study: 26888312

Group type: EXPERIMENTAL
Intervention: Compassion-focused imagery intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control imagery condition
Number of subjects: 51
Study: 27230437

Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring (RTMM) with tailored SMS reminders
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 209
Study: 25190425

Group type: EXPERIMENTAL
Intervention: Auditory training 2x/week for 15 sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory training 3x/week for 15 sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study: 22726281

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg once daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 50
Study: 19473334

Group type: EXPERIMENTAL
Intervention: Telephone administration after mail administration
Number of subjects: 447

Group type: COMPARATOR
Intervention: Mail administration first
Number of subjects: 447

Group type: COMPARATOR
Intervention: Telephone administration first
Number of subjects: 447
Study: 17167262

Group type: EXPERIMENTAL
Intervention: Acidic candy with calcium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acidic candy without calcium (control)
Number of subjects: 20
Study: 14693633

Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Circle system ventilation
Number of subjects: 41
Study: 12476290

Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine dipeptide (30 g i.v. from day +1 to day +14)
Number of subjects: 40
Study: 10439748

Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide/fentanyl (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol/fentanyl (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 20
Study: 7599546

Group type: EXPERIMENTAL
Intervention: Morphine combined with bupivacaine injected into the knee joint
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tourniquet time of 0 minutes
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tourniquet time of 8 minutes
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tourniquet time of 16 minutes
Number of subjects: 45
Study: 2238820

Group type: EXPERIMENTAL
Intervention: Elastic stockings (below-knee, elastic compression) for 12 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no compression)
Number of subjects: 140
Study: 393286

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study: 31849085

Group type: EXPERIMENTAL
Intervention: Albumin infusion (8 g/dL of ascitic fluid; n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No albumin (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Albumin infusion
Number of subjects: 80
Study: 30884808

Group type: EXPERIMENTAL
Intervention: SAx (Hydroxytyrosol 9.9 mg and Punicalagin 195 mg)
Number of subjects: 84
Study: 28489212

Group type: EXPERIMENTAL
Intervention: Protocol group with exams requested according to the study protocol
Number of subjects: 405

Group type: COMPARATOR
Intervention: Non-selectively requested exams group
Number of subjects: 405
Study: 26417002

Group type: EXPERIMENTAL
Intervention: Retinoblastoma survivors
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Bilateral RB survivors
Number of subjects: 470

Group type: COMPARATOR
Intervention: Unilateral RB survivors
Number of subjects: 470

Group type: COMPARATOR
Intervention: CCSS siblings
Number of subjects: 470
Study: 23719552

Group type: EXPERIMENTAL
Intervention: High-fat diet (37% of energy from fat and 50% of energy from carbohydrates)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fat diet (25% of energy from fat and 62% of energy from carbohydrates)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 12
Study: 21145053

Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 4966

Group type: EXPERIMENTAL
Intervention: Gabexate
Number of subjects: 4966

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 4966

Group type: EXPERIMENTAL
Intervention: High-quality studies on Ulinastatin
Number of subjects: 4966

Group type: COMPARATOR
Intervention: Other outcomes
Number of subjects: 4966
Study: 19122170

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: LDL-C
Number of subjects: 0
Study: 17676693

Group type: EXPERIMENTAL
Intervention: Women with bulimia nervosa
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study: 15377355

Group type: EXPERIMENTAL
Intervention: Two-compound product (TCP) containing calcipotriol (50 microg g(‐1)) and betamethasone dipropionate (0.5 mg g(‐1)) applied once or twice daily
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 microg g(‐1)) applied twice daily
Number of subjects: 828

Group type: COMPARATOR
Intervention: Vehicle (placebo) applied twice daily
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: TCP applied once daily
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Calcipotriol applied twice daily
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: TCP applied twice daily
Number of subjects: 828
Study: 11409676

Group type: EXPERIMENTAL
Intervention: Complete implant stabilised oral prostheses (IG)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: New conventional complete dentures (CDG2)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional dentures (CDG1)
Number of subjects: 83
Study: 9686717

Group type: EXPERIMENTAL
Intervention: Gowned patients
Number of subjects: 223

Group type: COMPARATOR
Intervention: Ungowned patients
Number of subjects: 223
Study: 9744214

Group type: EXPERIMENTAL
Intervention: Pre-procedural education/counselling program
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard ward care (comparison group)
Number of subjects: 130
Study: 1863741

Group type: EXPERIMENTAL
Intervention: Protamine sulfate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Protamine chloride
Number of subjects: 32
Study: 6685644

Group type: EXPERIMENTAL
Intervention: LMP/FVP
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: LMFP/ADM
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: low-dose chemotherapy (lmfp)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: bony metastases as dominant lesion
Number of subjects: 230
Study: 30541754

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 30145971

Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 706

Group type: COMPARATOR
Intervention: Multivessel PCI
Number of subjects: 706
Study: 26303102

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 24472854

Group type: COMPARATOR
Intervention: Sequential intervention (n=1736)
Number of subjects: 5055

Group type: COMPARATOR
Intervention: Simultaneous intervention (n=1638)
Number of subjects: 5055

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 5055
Study: 23350190

Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amixin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ridostin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribavirin in combination with cycloferon
Number of subjects: 0
Study: 21176627

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Early PCI (PCI within 24 h)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Delayed PCI (PCI after 36 h)
Number of subjects: 164

Group type: COMPARATOR
Intervention: No cilostazol
Number of subjects: 164
Study: 18935732

Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Povidone iodine followed by normal saline (control)
Number of subjects: 30
Study: 15811981

Group type: EXPERIMENTAL
Intervention: 380 mg long-acting naltrexone
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: 190 mg long-acting naltrexone
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 12535744

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45